Traitement en cours

Veuillez attendre...

PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le mardi 26.10.2021 à 12:00 PM CEST
Paramétrages

Paramétrages

Aller à Demande

1. WO2011056697 - MÉTHODES DE TRAITEMENT PAR VOIE TOPIQUE D'INFECTIONS PAR LE VIRUS RESPIRATOIRE SYNCYTIAL (RSV) ET D'ÉTATS ASSOCIÉS

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

WHAT IS CLAIMED:

1. A method of reducing respiratory syncytial virus (RSV) viral load in a human in need thereof, comprising a topical administration of an effective amount of a composition comprising a RSV antibody.

2. A method of preventing RSV viral load in a human in need thereof, comprising a topical administration of an effective amount of a composition comprising a RSV antibody.

3. The method of claim 1 or 2, wherein said human has chronic obstructi ve pulmonary disease (COPD).

4. The method of claim 1 or 2, wherein the human is an elderly human, or is living in a nursing home.

5. The method of claim 1 or 2, wherein said reduction of RSV viral load is by at least a 1.5 loglG, as measured by plaque culture of nasal washes or tracheal aspirate specimens.

6. The method of claim 1 or 2, wherein said reduction of RSV viral load is by at least a 2.0 log 10, as measured by plaque culture of nasal washes or tracheal aspirate specimens.

7. The method of claim 1 or 2, wherein said topical administration is by pulmonary

administration.

8. The method of claim 7, wherein said administration is via a nebulizer.

9. The method of claim 1 or 2, wherein the effective amount of said RSV antibody is selected from the group consisting of about 30 mg/kg, about 25 mg/kg, about 20 mg/kg, about 15 mg/kg, about 10 mg/kg, about 5 mg/kg, about 3 mg/kg, about 1.5 mg/kg, about 1 mg/kg, about 0.75 mg/kg, about 0.5 mg/kg, about 0.25 mg/kg, about 0.1 mg/kg, about 0.05 mg/kg, and about 0.025 mg/kg.

10. The method of claim 7, wherein the pulmonary administration of the effective amount of the composition is for a duration of up to 30 seconds, up to 1 minute, up to 5 minutes, for up to 10 minutes, for up to 20 minutes, for up to 30 minutes.

1 1. The method of claim 1 or 2, wherein the RSV antibody has one or more of the characteristics selected from the group consisting of:

(a) an inhibitory concentration IC50 of about 6 riM to about 0.01 nM in an in vitro microneutralization assay; and/or

(b) an affinity constant Ka rate of between 2 X 108M-1 and 5 X 1012M-1 , as measured by a Kinexa assay.

12. The method of claim 1, 2 or 11, wherein said RSV antibody immunospecifically binds an RSV F antigen,

13. The method of claim 1, 2 or 11, wherein said RSV antibody immunospecifically binds a RSV G antigen.

14. The method of claim 1 or 2, wherein said composition further comprises a second antibody.

15. The method of claim 1 or 2, wherein said RSV antibody is a bispecific antibody.

16). The method of claim 15, wherein said bispecific antibody immunospecifically binds an RSV F antigen and an RSV G antigen.

17. The method of claim 15 or 16, wherein said bispecific antibody is a modified antibody.